NCT02018874View on ClinicalTrials.gov

A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Solid Tumors and Non-Hodgkin's Lymphoma
Interventions
DRUG

LY2780301

"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D."

DRUG

Gemcitabine

The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT02018874 - A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine | Biotech Hunter | Biotech Hunter